1-5 of 5
Anshu Giri
Close
Sort by
Journal Articles

Phase I Study of Oral Azacitidine (CC-486) Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Brian T. Hess, Leandro Cerchietti, Lindsey Hendrickson, Elizabeth Hill, Anshu Giri, Shanta Salzer, Sarah Hogan, Lacey Finch, Robin Klingenberg, Fang Hu, Nina D. Wagner-Johnston
Journal: Blood
Blood (2021) 138 (Supplement 1): 3567.
https://doi.org/10.1182/blood-2021-145493
Published: 2021
Journal Articles

Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma

Brian T. Hess, MD, Anshu Giri, MD, Yeonhee Park, PhD, Krina K. Patel, MD, Brian K. Link, MD, Grzegorz S. Nowakowski, MD, Seth M Maliske, MD, Sonia Fortin, Julio C. Chavez, MD, Hayder Saeed, MD, Brian T. Hill, MD, Alex V. Mejia Garcia, MD, Kami J. Maddocks, MD, Walter Hanel, MD, Nina D. Wagner-Johnston, Marcus Raymond Messmer, MD, Brad S. Kahl, MD, Marcus Watkins, PhD, Juan Pablo Alderuccio, MD, Izidore S. Lossos, MD, Sunita Nathan, MD, Victor M. Orellana-Noia, MD, Craig A. Portell, MD, Daniel J. Landsburg, MD, Emily C. Ayers, MD, Jorge J. Castillo, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–16.
https://doi.org/10.1182/blood-2020-138536
Published: 2020
Journal Articles

Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers

Shalin K. Kothari, MD, Shaoying Li, MD, L. Jeffrey Medeiros, MD, Emily C. Ayers, MD, Daniel J. Landsburg, MD, David A. Bond, MD, Kami J. Maddocks, MD, Anshu Giri, MD, Brian T. Hess, MD, Luu Q. Pham, Ranjana Advani, MD, Yang Liu, MD, Stefan Klaus Barta, MDMRCP,MS, Julie M. Vose, MDMBA, Michael C. Churnetski, BS, Jonathon B. Cohen, MDMS, Madelyn Burkart, MD, Reem Karmali, MD, Joanna Zurko, MD, Amitkumar Mehta, MD, Adam J Olszewski, MD, Sarah S Lee, MD, Brian T. Hill, MD PhD, Timothy F. Burns, MD, Frederick Lansigan, MD, Emma Rabinovich, MD, David Peace, MD, Adrienne Groman, MS, Kris Attwood, PhD MS, Francisco J. Hernandez-Ilizaliturri, MD, Pallawi Torka, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 451.
https://doi.org/10.1182/blood-2018-99-111530
Published: 2018
Journal Articles

Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy

Emily C. Ayers, MD, Shaoying Li, MD, Jeffrey Medeiros, MD, David A. Bond, MD, Kami J. Maddocks, MD, Pallawi Torka, MD, Angel Mier Hicks, MD, Madeira Curry, Nina D. Wagner-Johnston, MD, Reem Karmali, MD, Amir Behdad, MD, Bita Fakhri, MDMPH, Brad S Kahl, MD, Michael C Churnetski, BS, Jonathon B. Cohen, MDMS, Nishitha Reddy, MD, Dipenkumar Modi, MD, Radhakrishnan Ramchandren, MD, Christina Howlett, PharmD, BCOP, Lori A. Leslie, MD, Samuel Cytryn, Catherine Diefenbach, MD, Rawan Faramand, MD, Julio C. Chavez, MD, Adam J Olszewski, MD, Yang Liu, MD, Stefan Klaus Barta, MDMRCP,MS, Dhruvika Mukhija, MD, Brian T. Hill, MD PhD, Helen Ma, MD, Jennifer E Amengual, MD, Sunita Nathan, MD, Sarit Assouline, Victor M. Orellana-Noia, MD, Craig A. Portell, MD, Ashwin Chandar, MD, Kevin A. David, MD, Anshu Giri, MD, Brian T. Hess, MD, Daniel J. Landsburg, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 453.
https://doi.org/10.1182/blood-2018-99-115527
Published: 2018
Journal Articles

Surface Plasmon Resonance Study of Apoptotic Regulators Bcl-2, Bcl-w, Bcl-XL, and Mcl-1 Indicate That the Preclinical Small Molecule Inhibitor (SMI) TW-37 Binds to the Hydrophobic Groove Competitively with tBid To Form a Heterodimer Which Cannot Be Disrupted by 200-Fold Molar Excess of TW-37.

Anton-Scott Goustin, PhD, Anshu Giri, B.S., Shaomeng Wang, Ph.D., Ayad Al-Katib, M.D., Mohammad M. Ramzi, Ph.D.
Journal: Blood
Blood (2007) 110 (11): 1606.
https://doi.org/10.1182/blood.V110.11.1606.1606
Published: 2007